Kriya was founded on a simple belief: Medicine can do more.

Mission

For millions of people, treatment for a chronic disease means a lifetime of doctor appoint­ments, scheduling infusions, refilling pre­scrip­tions, and suffering through off-target side effects. His­tor­i­cal­ly, there was no alternative. Now, break­throughs in science have opened the door to a better paradigm for patients.

Colleagues talking over a monitor in an open plan office
Two scientists in blue lab coats connecting tubing to buffer bottles
Two lab workers in white cleanroom suits hairnets and safety glasses read machine data

kriya (KREE-yuh)

Sanskrit for ​“action,” reflecting our belief that trans­for­ma­tive science creates impact only when it is translated into medicines that reach patients.

For the first time, science has made it possible to treat diseases with therapies designed to last for years, or potentially a lifetime, from a single dose.

Patients born with inherited blindness and deafness have regained vision and hearing. Children with spinal muscular atrophy have achieved devel­op­men­tal milestones once thought impossible. The first generation of durable medicines has already proven that life-changing effects are achievable.

The question is no longer whether durable medicines are sci­en­tif­i­cal­ly possible. The question is how they can scale.

The single greatest obstacle standing between today’s break­throughs becoming tomorrow’s standards of care is no longer science.

It is infra­struc­ture. More specif­i­cal­ly, it is the physical and digital toolkit needed to solve the cost and complexity of developing and man­u­fac­tur­ing durable medicines at scale. Given these challenges, durable medicines have his­tor­i­cal­ly been made in piecemeal fashion, including outsourcing to a network of specialized third-party providers. Piecemeal outsourcing leads to fragmented data, compounding the challenge.

That is why we started Kriya.

Delivering durable medicines at scale requires marrying leading-edge man­u­fac­tur­ing capability with large integrated datasets. This neces­si­tates owning the complete technology stack — and operating that infra­struc­ture with conviction. Durable medicines will define the next century of healthcare. We believe Kriya will unlock this future.

Because of our emphasis on long-term impact, we may make decisions differently from many biotech­nol­o­gy companies. Accordingly, we want to share the principles that guide our thinking.

Our principles

We will focus relent­less­ly on patients.

Every decision begins with a singular question: Does this reduce the burden of disease for patients? That is our only goal.

01

We will challenge industry assumptions.

We believe many of the most important problems in healthcare remain unsolved because they have been accepted as inevitable. We do not share this view.

02

We will integrate rather than fragment.

“Functions” – research, man­u­fac­tur­ing, clinical development, commercial, etc. – should not operate inde­pen­dent­ly. They should operate as a single system powered by large integrated data.

03

We will build for the many, not the few.

We believe durable medicines should ultimately reach everyone. Scale is not an aspiration. It is the objective.

04

We will prioritize our long-term mission over short-term distractions.

We will continue to invest in capa­bil­i­ties that strengthen our ability to com­mer­cial­ize durable medicines at scale, even when those investments are difficult to appreciate in the short term.

05

We will make bold decisions when conviction warrants it.

Some projects will work. Others will not. We would rather learn from ambitious decisions than be constrained by not thinking big.

06

We will commit to a better future.

We are building for the next 100 years and beyond. We want better medicines and a healthier future – not just for our children, but their grandchildren.

07

The Durable Medicines Company.

Kriya is building the infra­struc­ture layer for durable medicines. The systems required to transform durable medicines from a scientific possibility into a scalable reality. Tech­nolo­gies and modalities will evolve. New scientific break­throughs will emerge. But the need for this core foun­da­tion­al infra­struc­ture will remain. Over time, this infra­struc­ture will become more valuable, not less. 

The first generation of durable medicines proved what is possible. Our mission is to make them scalable. Because millions of patients deserve better.

Shankar Ramaswamy, M.D.

Co-Founder & Chief Executive Officer
Kriya Ther­a­peu­tics

We’re bringing together the brightest minds to shape the future of medicine. Meet Our Experts Kriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice Kriya Selected for FDA PreCheck Pilot Program

Disclaimer

Kriya’s durable medicines are inves­ti­ga­tion­al and have not been approved as safe or effective by any regulatory health authority.